2025-06-09-Jefferies-Ascendis制药（ASND）_TransCon_hGH在软骨发育不全中与CNP显示出强大的协同效应_11页_633kb
报告摘要
- Study Summary: Ascendis Pharma's TransCon CNP + TransCon hGH combo in Study Ph2 COACH trial showed a 4.23 cm/yr baseline-adjusted annual growth velocity (AGV) at week 26 in treatment-naïve achondroplasia patients, > doubling the efficacy of CNP monotherapy (~1.94 cm/yr). efficacy was also notable in CNP-treated patients with comparable safety profiles.
- Synergy and Expansion: The combo enhances CNP’s commercial competitiveness due to superior efficacy, quarterly dosing (~1 injection/month), and co-formulation potential. Company plans to expand to additional indications.
- Market Share & Price Target: Jefferies Equity Research raises ASND market share estimate from 40% to 50% (net penetration ~30%), leading to a 35% price target increase to $233 (previously $173.06).
- Financial Projections: Achieves $450M peak sales for TransCon CNP in achondroplasia by 2035 (up from $360M previously). Total 2035 revenue from Skytrofa (~$700M) and TransCon PTH (~$3.1B) supports valuation.
- Valuation: Equity Research assigns a $233 price target based on a DCF model, 9.0% WACC, and terminal growth rate of 0%. Sensitivity analysis indicates higher valuation with lower discount rates.
- Analyst Certification: All Jefferies analysts confirm the views reflect personal judgments.
展开完整摘要
试读结束，高清完整版pdf/doc/ppt,请点下载
